Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication

Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, Stefan Schmitl, Hans-Juergen Wester, Alexander Haug

Blood (2022) 139 (2): 240–244.

https://doi.org/10.1182/blood.2021013239

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer

Cornelia Englisch, Florian Moik, Stephan Nopp, Markus Raderer, Ingrid Pabinger, Cihan Ay

Blood (2021) 138 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2021-145713

Published: 2021

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

A MALT lymphoma prognostic index

Catherine Thieblemont, Luciano Cascione, Annarita Conconi, Barbara Kiesewetter, Markus Raderer, Gianluca Gaidano, Maurizio Martelli, Daniele Laszlo, Bertrand Coiffier, Armando Lopez Guillermo, Valter Torri, Franco Cavalli, Peter W. Johnson, Emanuele Zucca

Blood (2017) 130 (12): 1409–1417.

https://doi.org/10.1182/blood-2017-03-771915

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer

Blood (2017) 129 (3): 383–385.

https://doi.org/10.1182/blood-2016-06-720599

Published: 2017

Journal Articles

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Barbara Kiesewetter, Markus Raderer

Blood (2013) 122 (8): 1350–1357.

https://doi.org/10.1182/blood-2013-02-486522

Published: 2013

Journal Articles

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Andrés J. M. Ferreri, Silvia Govi, Markus Raderer, Antonino Mulè, Alessandro Andriani, Daniele Caracciolo, Liliana Devizzi, Fiorella Ilariucci, Stefano Luminari, Edi Viale, Leonhard Müllauer, Stefania Dell'Oro, Paolo Giorgio Arcidiacono, Maurilio Ponzoni, Caterina Patti

Blood (2012) 120 (18): 3858–3860.

https://doi.org/10.1182/blood-2012-06-438424

Published: 2012

Journal Articles

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

Blood (2011) 118 (21): 880.

https://doi.org/10.1182/blood.V118.21.880.880

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Silvia Govi, MD, Caterina Patti, MD, Markus Raderer, MD, Alessandro Andriani, MD, Daniele Caracciolo, MD, Anna Guidetti, MD, Fiorella Ilariucci, MD, Stefano Luminari, MD, Antonino Mulè, MD, Edi Viale, MD, Paolo Giorgio Arcidiacono, MD, Maurilio Ponzoni, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 958.

https://doi.org/10.1182/blood.V118.21.958.958

Published: 2011

Journal Articles

PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG

Blood (2010) 116 (21): 1770.

https://doi.org/10.1182/blood.V116.21.1770.1770

Published: 2010

Journal Articles

Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well as T/NK-Cell Lymphomas and Cardiac Comorbidity or Older Age

Cathri n C Skrabs, Alexander Hauswirth, Karin Eigenberger, Christine Einberger, Markus Raderer, Wolfgang R Sperr, Paul Knoebl, Leonhard Muellauer, Martin Uffmann, Karin Dieckmann, Alexander Gaiger, Ulrich Jaeger, MD

Blood (2008) 112 (11): 3587.

https://doi.org/10.1182/blood.V112.11.3587.3587

Published: 2008

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Holzer, MD, Viktoria Odelga, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2007) 110 (11): 2578.

https://doi.org/10.1182/blood.V110.11.2578.2578

Published: 2007

Journal Articles

Mosaicism due to myeloid lineage–restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting

Günther F. Körmöczi, Eva-Maria Dauber, Oskar A. Haas, Tobias J. Legler, Frederik B. Clausen, Gerhard Fritsch, Markus Raderer, Christoph Buchta, Andreas L. Petzer, Diether Schönitzer, Wolfgang R. Mayr, Christoph Gassner

Blood (2007) 110 (6): 2148–2157.

https://doi.org/10.1182/blood-2007-01-068106

Published: 2007

Journal Articles

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Johannes Drach, MD, Hannes Kaufmann, MD, Oskar Pichelmayer, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andreas Chott, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2006) 108 (11): 2753.

https://doi.org/10.1182/blood.V108.11.2753.2753

Published: 2006

Journal Articles

Genetic Heterogeneity in MALT Lymphoma.

Berthold Streubel, Markus Raderer, Andreas Chott

Blood (2006) 108 (11): 355.

https://doi.org/10.1182/blood.V108.11.355.355

Published: 2006

Journal Articles

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Christian Schuetzinger, Harald Esterbauer, MD,PhD, Cathrin Skrabs, MD, Martin Uffmann, MD, Markus Raderer, MD, Alexander Hauswirth, MD, Alexander Gaiger, MD, Christine Mannhalter, PhD, Karin Dieckmann, MD, Oswald Wagner, MD, Ulrich Jaeger, MD

Blood (2006) 108 (11): 2060.

https://doi.org/10.1182/blood.V108.11.2060.2060

Published: 2006

Journal Articles

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

Johannes Drach, MD, Sonja Seidl, MD, Oskar Pichelmayer, MD, Hannes Kaufmann, MD, Christoph Zielinski, MD, Markus Raderer, MD

Blood (2005) 106 (11): 4799.

https://doi.org/10.1182/blood.V106.11.4799.4799

Published: 2005

Journal Articles

t(3;14)(P14.1;Q32) Involving IGH and FOXP1 Is a Recurrent Chromosomal Aberration in MALT Lymphoma.

Berthold Streubel, MD, Ursula Vinatzer, PhD, Andrea Lamprecht, Markus Raderer, MD, Andreas Chott, MD

Blood (2004) 104 (11): 550.

https://doi.org/10.1182/blood.V104.11.550.550

Published: 2004

Journal Articles

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Hannes Kaufmann, Markus Raderer, Stefan Wöhrer, Andreas Püspök, Alexander Bankier, Christoph Zielinski, Andreas Chott, Johannes Drach

Blood (2004) 104 (8): 2269–2271.

https://doi.org/10.1182/blood-2004-03-1091

Published: 2004

NARROW

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication

Impact of ABO Blood Group Type on Risk of Venous Thromboembolism in Patients with Cancer

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

A MALT lymphoma prognostic index

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG

Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well as T/NK-Cell Lymphomas and Cardiac Comorbidity or Older Age

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission.

Mosaicism due to myeloid lineage–restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting

Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Genetic Heterogeneity in MALT Lymphoma.

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Promising Activity of Bortezomib, Rituximab, and Dexamethason (BORID) in Patients with Relapsed Mantle Cell Lymphoma.

t(3;14)(P14.1;Q32) Involving IGH and FOXP1 Is a Recurrent Chromosomal Aberration in MALT Lymphoma.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only